Our @TheLancetPsych paper describes a digital tool https://t.co/jfchQvzQwB that facilitates evidence-based, personalised, and collaborative antidepressant and antipsychotic prescribing based on medication side-effects. https://t.co/AxkPZdKFp3 1/n

Not all #antidepressants are the same. New research from @KingsCollegeLon (@tobypill) and @UniofOxford (@And_Cipriani) has ranked 30 different #SSRIs and assessed their impact on a range of side effects on users physical health. Read more: https://t.co/tfDSOWBuyj

🚨 New Publication🚨 @tobypill et. al 'The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis' in @TheLancet Read more!👇 https://t.co/doqf7YJwsF #metabolicpsychiatry #metabolichealth

"How do we speak to our patients about the metabolic challenges that they might face?" We're excited to share our brand new podcast on 'Psychiatry and physical health' featuring: @tobypill and @dredbeveridge 🔗 https://t.co/oUFk4RcC2q

I really enjoyed this discussion with @tobypill where we talk about we can do to prevent early death in people with mental illness. Great palate cleanser for the nourishing @TheLancet Commission paper out this week. 🚨🚨🚨 SMASH THAT SHARE BUTTON FOLKS 💥💥💥 @rcpsych

Another great paper from @TheLancet Commission this time about prevention and management of adverse effects of psychotropic medication #parityofesteem #mortalitygap @rcpsych @tobypill @DrLadeSmith https://t.co/61EmnCePlM

It was great to launch our international guidelines for treatment of schizophrenia at the @SIRSGlobal annual congress - many thanks to all those who contributed, especially @rob_mccutcheon Read here: https://t.co/1u0NoACfRb Use the digital tool: https://t.co/jfchQvzQwB

Yesterday, I presented @AstonUniversity on my own weight journey and lived experience involvement in the @NIHRresearch funded #RESOLVE study. Blog here ➡️ https://t.co/gk9TZ0GhR8 @PharMED_ @Prof_Ian_M @DrJoHowe @Hafsah_Habib @KEPatersonRD @IainCampbellPhD @benjmnperry @tobypill

New paper with @Matt_Nour , @tobypill , and Phil Cowen discussing different ways of thinking about and developing psychopharmacological treatments

Our guideline for the use of metformin to prevent antipsychotic-induced weight gain has just been published in Schizophrenia Bulletin. Read the full paper here: https://t.co/ov7R3rjTy6 A 🧵of the key points

Rolling Thunder - An evening with Professor John Kane | King's College London This will be a pleasure- pioneered use of clozapine, 900 papers, 24 NIH grants, now pro 1st episode services. And (annoyingly)renaissance man. Next Friday ⁦@KingsIoPPN⁩ ⁦

An evening in conversation with Professor John Kane, hosted by @KingsIoPPN. A global leader of psychosis research interviewed by the inimitable @sameerjauhar – open to all and not to be missed! https://t.co/xb4GXLCPJf

Monday 30th Sept I will attend a symposium on #metabolic #psychiatry at University of Bari 🇮🇹. Title of my talk "Omics Dissection of #Depression Heterogeneity: Toward Immunometabolic Depression". Great panel with @tobypill @EttaNettis @enricodam @giufanelli and many others!

Come and help us set up a clinic at the Maudsley focussing on the cognitive and metabolic health of people with psychotic disorders, and also gain research experience in the cardiometabolic health of people with SMI 🧠🫀💪 Apply here: https://t.co/taOnZibaYC

We are delighted that King's researchers Professor Khalida Ismail, Dr Toby Pillinger @tobypill, Professor Fiona Gaughran @FGaughran and Dina Farran, will be working as part of this new Hub on novel interventions.

The MPG International Conference 2025 will take place on Thursday 10th April 2025 at @KingsIoPPN. Registration will be available soon. For more details, please visit: https://t.co/XW5hy86U7K

Come and help us develop metabolic interventions for people with serious mental illness! We're looking for a post-doc for our @UKRI_News 'Hub for Metabolic Psychiatry' based @KingsIoPPN with myself, @FGaughran and Khalida Ismail

These data can be incorporated into digital clinical tools to facilitate personalised prescribing and shared decision making e.g., https://t.co/jfchQvzQwB FIN

Risperidone, quetiapine, and olanzapine are 3 of the 4 most prescribed APs for children, so our findings have implications for clinical practice. Aripiprazole, blonanserin, lurasidone, molindone, and ziprasidone can be broadly considered safer treatment options.

The physiological effects of antipsychotics did not seem to be influenced by demographics, baseline physiology, or diagnosis, so findings can be considered robust and generalisable across the paediatric population.

We also saw large changes in heart rate and blood pressure associated with some antipsychotics. For example, compared to placebo, quetiapine was associated with an increase in HR of 12bpm, and systemic blood pressure went up by 10mmHg